Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Pancreatic Cancer
Interventions
RADIATION

Stereotactic Body Radiotherapy

Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator

DRUG

Gemcitabine

Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes

OTHER

4D pancreatic protocol CT scan

Patients will undergo this imaging procedure prior to treatment for planning purposes.

RADIATION

FDG PET scan

Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

All Listed Sponsors
lead

Albert Koong

OTHER

NCT00350142 - Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer | Biotech Hunter | Biotech Hunter